var data={"title":"Iron dextran: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Iron dextran: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6403?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=iron-dextran-patient-drug-information\" class=\"drug drug_patient\">see &quot;Iron dextran: Patient drug information&quot;</a> and <a href=\"topic.htm?path=iron-dextran-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Iron dextran: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708946\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Anaphylactic-type reactions:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Anaphylactic-type reactions, including fatalities, have followed the parenteral administration of iron dextran injection. Have resuscitation equipment and personnel trained in the detection and treatment of anaphylactic-type reactions readily available during iron dextran administration.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Administer a test dose of iron dextran prior to the first therapeutic dose. If no signs or symptoms of anaphylactic-type reactions follow the test dose, administer the full therapeutic iron dextran dose. During all iron dextran administrations, observe for signs or symptoms of anaphylactic-type reactions. Fatal reactions have followed the test dose of iron dextran injection. Fatal reactions have also occurred in situations in which the test dose was tolerated.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Patients with a history of drug allergy or multiple drug allergies may be at increased risk of anaphylactic-type reactions to iron dextran.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Appropriate use: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Use iron dextran only in patients in whom clinical and laboratory investigations have established an iron-deficient state not amenable to oral iron therapy. </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184543\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Dexferrum [DSC];</li>\n      <li>Infed</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184544\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Dexiron;</li>\n      <li>Infufer</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184562\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Iron Salt</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184546\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: Dexferrum has been discontinued in the US for more than 1 year.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> A 0.5 mL test dose should be given prior to starting iron dextran therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Iron-deficiency anemia:</b> IM (INFeD), IV (Dexferrum, INFeD):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dose (mL) = 0.0442 (desired hemoglobin - observed hemoglobin) x LBW + (0.26 x LBW)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Desired hemoglobin: Usually 14.8 g/dL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">LBW = Lean body weight in kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Iron replacement therapy for blood loss:</b> (INFeD), IV (Dexferrum, INFeD): Replacement iron (mg) = blood loss (mL) x Hct</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Maximum daily dosage:</b>  Manufacturer's labeling: <b>Note:</b> Replacement of larger estimated iron deficits may be achieved by serial administration of smaller incremental dosages. Daily dosages should be limited to 100 mg iron (2 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cancer-/chemotherapy-associated anemia:</b> IV: <b>Note:</b> Use the iron-deficiency anemia equation for determining a calculated dose, when applicable.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Weekly administration (off-label dosing; INFed):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Weeks 1-3: Test dose of 25 mg (over 1-2 minutes), followed by 75 mg (bolus) once weekly</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Weeks 4 and after: 100 mg over 5 minutes once weekly until the calculated dose is reached (Auerbach, 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Week 1: Test dose of 25 mg (slow IV push), followed 1 hour later by 75 mg over 5 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Weeks 2-10: 100 mg over 5 minutes once weekly for a total cumulative dose of 1000 mg (NCCN anemia guidelines v.2.2014)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Total dose infusion (off-label dosing; INFeD):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Test dose of 25 mg (over 1-2 minutes), followed 1 hour later by the balance of the calculated total dose mixed in 500 mL NS and infused at 175 mL/hour (Auerbach, 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Test dose of 25 mg (slow IV push) followed 1 hour later by the balance of the total dose as a single infusion over several hours; if calculated dose exceeds 1000 mg, administer remaining dose in excess of 1000 mg after 4 weeks if inadequate hemoglobin response (NCCN anemia guidelines v.2.2014)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184556\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=iron-dextran-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Iron dextran: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: Dexferrum has been discontinued in the US for more than 1 year.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> A 0.5 mL test dose (0.25 mL in infants) should be given prior to starting iron dextran therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Iron-deficiency anemia:</b> IM (INFeD), IV (Dexferrum, INFeD):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children  5-15 kg: Should not normally be given in the first 4 months of life:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dose (mL) = 0.0442 (desired hemoglobin - observed hemoglobin) x W + (0.26 x W)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Desired hemoglobin: Usually 12 g/dL</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">W = Total body weight in kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &gt;15 kg: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Iron replacement therapy for blood loss:</b> Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Maximum daily dose:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &lt;5 kg: 25 mg iron (0.5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 5-10 kg: 50 mg iron (1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;10 kg: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184547\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16160032\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Hemodialysis: Nondialyzable. No dosage adjustment provided in manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16160033\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment provided in manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184523\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dexferrum: 50 mg/mL (1 mL [DSC], 2 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infed: 50 mg/mL (2 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184507\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21963476\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Strength of iron dextran complex is expressed as elemental iron.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49263683\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dexferrum has been discontinued in the US for more than 1 year.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184528\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> A test dose should be given on the first day of therapy; patient should be observed for 1 hour for hypersensitivity reaction, then the remainder of the day&rsquo;s dose (dose minus test dose) should be given. Resuscitation equipment, medication, and trained personnel should be available. An uneventful test dose does not ensure an anaphylactic-type reaction will not occur during administration of the therapeutic dose. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IM (INFeD): Use Z-track technique (displacement of the skin laterally prior to injection); injection should be deep into the upper outer quadrant of buttock; alternate buttocks with subsequent injections. Administer test dose at same recommended site using the same technique. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IV: Test dose should be given gradually over at least 30 seconds (INFeD) or 5 minutes (Dexferrum), or over 1-2 minutes (INFeD) for cancer-/chemotherapy-associated anemia (Auerbach, 2004). Subsequent dose(s) may be administered by IV bolus undiluted at a rate not to exceed 50 mg/minute (maximum 100 mg). For total dose infusion in patients with cancer-/chemotherapy-associated anemia (off-label dose): 1 hour after the test dose, administer the balance of the dose diluted in 500 mL NS and infuse at 175 mL/hour (Auerbach, 2004) or administer over several hours (NCCN Anemia guidelines v.2.2104). Avoid dilutions with dextrose (increased incidence of local pain and phlebitis).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184527\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Iron deficiency:</b> Treatment of iron deficiency in patients in whom oral administration is unsatisfactory or infeasible</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184569\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Dexferrum may be confused with Desferal</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Iron dextran complex may be confused with ferumoxytol</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184514\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined. Adverse event risk is reported to be higher with the high-molecular-weight iron dextran formulation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Bradycardia, cardiac arrhythmia, chest pain, chest tightness, flushing, hypertension, hypotension, shock, syncope, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Chills, disorientation, dizziness, headache, loss of consciousness, malaise, paresthesia, seizure, unresponsive to stimuli</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Diaphoresis, pruritus, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, diarrhea, dysgeusia, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Hematuria, urine discoloration</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Leukocytosis, lymphadenopathy, purpura</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylaxis (includes acute respiratory distress, circulatory shock)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Sterile abscess</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Injection site reaction (includes injection site cellulitis, inflammation at injection site, injection site phlebitis, local soreness/soreness at injection site, pain at injection site, swelling at injection site), local discoloration (at the site of intramuscular injection)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Amyotrophy (with intramuscular injection), arthralgia, arthritis, back pain, exacerbation of arthritis, myalgia, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Bronchospasm, cyanosis, dyspnea, wheezing</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever, fibrosis (with intramuscular injection)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Angioedema, neoplasm (at former injection site)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184531\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to iron dextran or any component of the formulation; any anemia not associated with iron deficiency</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184511\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Delayed reaction: Delayed (1-2 days) infusion reaction (including arthralgia, back pain, chills, dizziness, and fever) may occur with large doses (eg, total dose infusion) of IV iron dextran; usually subsides within 3-4 days. May also occur (less commonly) with IM administration; subsiding within 3-7 days.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity/anaphylactoid reactions: <b> [U.S. Boxed Warning]: Deaths associated with parenteral administration following anaphylactic-type reactions have been reported (use only where resuscitation equipment and personnel are available). A test dose should be administered to all patients prior to the first therapeutic dose. Anaphylactic and other hypersensitivity reactions have occurred even in patients who tolerated the test dose; observe for anaphylactic reactions during any iron dextran administration; fatalities have occurred with the test dose. A history of  drug allergy (including multiple drug allergies) and/or the concomitant use of an ACE inhibitor may increase the risk of anaphylactic-type reactions.</b> Adverse events (including life-threatening) associated with iron dextran usually occur more with the high-molecular-weight formulation (Dexferrum), compared to low-molecular-weight (INFeD) (Chertow, 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Allergies/asthma: Use with caution in patients with a significant history of allergies or asthma.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cancer-associated anemia: In patients with cancer-related anemia (either due to cancer or chemotherapy-induced) requiring iron supplementation, the IV route is superior to oral therapy; IM administration is not recommended for parenteral iron supplementation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiovascular disease: Use with caution in patients with pre-existing cardiovascular disease; iron dextran may exacerbate cardiovascular complications.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with extreme caution in patients with serious hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal disease/impairment: In patients with chronic kidney disease (CKD) requiring iron supplementation, the IV route is preferred for hemodialysis patients; either oral iron or IV iron may be used for nondialysis and peritoneal dialysis CKD patients. Avoid use during acute kidney infection.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Rheumatoid arthritis: Use with caution in patients with rheumatoid arthritis; may exacerbate joint pain and swelling. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: Anemia in the elderly is often caused by &ldquo;anemia of chronic disease&rdquo; or associated with inflammation rather than blood loss. Iron stores are usually normal or increased, with a serum ferritin &gt;50 ng/mL and a decreased total iron binding capacity. IV administration of iron dextran is often preferred over IM in the elderly secondary to a decreased muscle mass and the need for daily injections.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pediatric: Intramuscular iron dextran use in neonates may be associated with an increased incidence of gram-negative sepsis. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Product interchangeability: Iron dextran products differ in chemical characteristics. The high-molecular-weight formulation (Dexferrum) and the low-molecular-weight formulation (INFeD) are not clinically interchangeable.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: <b>[U.S. Boxed Warning]: Use only in patients where the iron deficient state is not amenable to oral iron therapy.</b> Discontinue oral iron prior to initiating parenteral iron therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Carcinogenicity: Intramuscular injections of iron-carbohydrate complexes may have a risk of delayed injection site tumor development.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Iron overload: Exogenous hemosiderosis may result from excess iron stores; patients with refractory anemias and/or hemoglobinopathies may be prone to iron overload with unwarranted iron supplementation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299544\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184516\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8574&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin-Converting Enzyme Inhibitors: May enhance the adverse/toxic effect of Iron Dextran Complex. Specifically, patients receiving an ACE inhibitor may be at an increased risk for anaphylactic-type reactions. Management: Follow iron dextran recommendations closely regarding both having resuscitation equipment and trained personnel on-hand prior to iron dextran administration and the use of a test dose prior to the first therapeutic dose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bictegravir: Iron Salts may decrease the serum concentration of Bictegravir.  Management: Bictegravir, emtricitabine, and tenofovir alafenamide can be administered with iron salts under fed conditions, but coadministration with or 2 hours after an iron salt is not recommended under fasting conditions.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimercaprol: May enhance the nephrotoxic effect of Iron Salts.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184519\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6792945\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. It is not known if iron dextran (as iron dextran) crosses the placenta. It is recommended that pregnant women meet the dietary requirements of iron with diet and/or supplements in order to prevent adverse events associated with iron deficiency anemia in pregnancy. Treatment of iron deficiency anemia in pregnant women is the same as in nonpregnant women and in most cases, oral iron preparations may be used. Except in severe cases of maternal anemia, the fetus achieves normal iron stores regardless of maternal concentrations.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6792947\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Trace amounts of iron dextran (as iron dextran) are found in human milk. Iron is normally found in breast milk. Breast milk or iron fortified formulas generally provide enough iron to meet the recommended dietary requirements of infants. The amount of iron in breast milk is generally not influenced by maternal iron status.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184521\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Hemoglobin, hematocrit, reticulocyte count, serum ferritin, serum iron, TIBC; monitor for anaphylaxis/hypersensitivity reaction (during test dose and therapeutic dose) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184524\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hemoglobin: Adults: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Males: 13.5-16.5 g/dL </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Females: 12.0-15.0 g/dL </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Serum iron: 40-160 mcg/dL </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Total iron binding capacity: 230-430 mcg/dL </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Transferrin: 204-360 mg/dL </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Percent transferrin saturation: 20% to 50%</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184510\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">The released iron, from the plasma, eventually replenishes the depleted iron stores in the bone marrow where it is incorporated into hemoglobin</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184530\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Hematologic response to either oral or parenteral iron salts is essentially the same; red blood cell form and color changes within 3 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Maximum effect: Peak reticulocytosis occurs in 5 to 10 days, and hemoglobin values increase within 2 to 4 weeks; serum ferritin peak: 7 to 9 days after IV dose </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IM: 60% absorbed after 3 days; 90% after 1 to 3 weeks, the balance is slowly absorbed over months  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IV: Uptake of iron by the reticuloendothelial system appears to be constant at about 10 to 20 mg/hour </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine and feces via reticuloendothelial system</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323229\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Infed Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/mL (2 mL): $31.82</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184533\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Cosmofer (AE, AT, CN, DE, DK, ES, FI, GB, GR, ID, IE, JO, KR, KW, LT, LV, MY, NL, NO, PH, PL, PT, QA, SA, SE, TH, VE);</li>\n      <li>Desman (TW);</li>\n      <li>Driken (MX);</li>\n      <li>Fexibron (PE);</li>\n      <li>Fexiron (AR, PE, PY);</li>\n      <li>Imferon (AE, BH, CU, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, TR, YE);</li>\n      <li>Intrafer (AR);</li>\n      <li>Supral (IN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Auerbach M, Ballard H, Trout JR, et al, &ldquo;Intravenous Iron Optimizes the Response to Recombinant Human Erythropoietin in Cancer Patients With Chemotherapy-Associated Anemia: A Multicenter, Open-Label, Randomized Trial,&rdquo; <i>J Clin Oncol</i>, 2004, 22(7):1301-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iron-dextran-drug-information/abstract-text/15051778/pubmed\" target=\"_blank\" id=\"15051778\">15051778</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Auerbach M, Witt D, and Toler W, &ldquo;Clinical Use of the Total Dose Intravenous Infusion of Iron Dextran,&rdquo; <i>J Lab Clin Med</i>, 1988, 111(5):566-70. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iron-dextran-drug-information/abstract-text/3361236/pubmed\" target=\"_blank\" id=\"3361236\">3361236</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Benito RP and Guerrero TC, &ldquo;Response to a Single Intravenous Dose Versus Multiple Intramuscular Administration of Iron Dextran Complex: A Comparative Study,&rdquo; <i>Curr Ther Res Clin Exp</i>, 1973, 15(7):373-82. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iron-dextran-drug-information/abstract-text/4198298/pubmed\" target=\"_blank\" id=\"4198298\">4198298</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chertow GM, Mason PD, Vaage-Nilsen O, et al, &ldquo;Update on Adverse Drug Events Associated With Parenteral Iron,&rdquo; <i>Nephrol Dial Transplant</i>, 2006, 21(2):378-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iron-dextran-drug-information/abstract-text/16286429/pubmed\" target=\"_blank\" id=\"16286429\">16286429</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dexferrum (iron dextran complex) [prescribing information]. Shirley, NY: American Regent; August 2008.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    INFeD (iron dextran complex) [prescribing information]. Morristown, NJ: Watson; January 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lipschitz DA, &ldquo;The Anemia of Chronic Disease,&rdquo; <i>J Am Geriatr Soc</i>, 1990, 38(11):1258-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iron-dextran-drug-information/abstract-text/2123218/pubmed\" target=\"_blank\" id=\"2123218\">2123218</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Practice Guidelines in Oncology&trade;: Cancer- and Chemotherapy-Induced Anemia Version 2.2014.&rdquo; Available at http://www.nccn.org/professionals/physician_gls/PDF/anemia.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Kidney Foundation, &ldquo;KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease,&rdquo; Am J Kidney Dis, 2007, 50(3):529-30. Available at http://www2.kidney.org/professionals/KDOQI/guidelines_anemiaUP/</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rizzo JD, Brouwers M, Hurley P, et al, &ldquo;American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update on the Use of Epoetin and Darbepoetin in Adult Patients With Cancer,&rdquo; <i>J Clin Oncol</i>, 2010, 28(33):4996-5010.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iron-dextran-drug-information/abstract-text/20975064/pubmed\" target=\"_blank\" id=\"20975064\">20975064</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rizzo JD, Somerfield MR, Hagerty LK, et al, &ldquo;American Society of Hematology/American Society of Clinical Oncology 2007 Clinical Practice Guideline Update on the Use of Epoetin and Darbepoetin,&rdquo; <i>Blood</i>, 2008, 111(1):25-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iron-dextran-drug-information/abstract-text/17954703/pubmed\" target=\"_blank\" id=\"17954703\">17954703</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8574 Version 127.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708946\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F184543\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F184544\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F184562\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F184546\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F184556\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F184547\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F16160032\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F16160033\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F184523\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F184507\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F21963476\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F49263683\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F184528\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F184527\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F184569\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F184514\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F184531\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F184511\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299544\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F184516\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F184519\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F6792945\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F6792947\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F184521\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F184524\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F184510\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F184530\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323229\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F184533\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8574|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=iron-dextran-patient-drug-information\" class=\"drug drug_patient\">Iron dextran: Patient drug information</a></li><li><a href=\"topic.htm?path=iron-dextran-pediatric-drug-information\" class=\"drug drug_pediatric\">Iron dextran: Pediatric drug information</a></li></ul></div></div>","javascript":null}